nach oben

Journal of Management and Governance

Erschienen in:

01.08.2012

Biotechnology collaborations: does business model matter?

verfasst von: Raphael Greiner, Siah Hwee Ang

Erschienen in: Journal of Management and Governance | Ausgabe 3/2012

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

This study investigates how a biotechnology firm’s collaboration incidence is affected by the business model it adopts. Specifically, we compare interfirm collaboration conducted by biopharmaceutical firms adopting the hybrid business model with those using the product-focused business model. The analysis based on 1,820 collaborations conducted by 87 dedicated biopharmaceutical firms suggests that firms adopting the hybrid business model generally engage in more collaboration. They also establish a greater proportion of exploration collaboration. These findings have implications for firm’s positioning using business models.

Vorheriger Artikel Transnational social capital and scientist entrepreneurship

Nächster Artikel Innovation and export performance: a study of Italian high-tech SMEs

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Ahuja, G. (2000). The duality of collaboration: Inducements and opportunities in the formation of interfirm linkages. Strategic Management Journal, 21(3), 317–343.CrossRef

Amir-Aslani, A., & Negassi, S. (2006). Is technology integration the solution to biotechnology’s low research and development productivity? Technovation, 26(5–6), 573–582.CrossRef

Amit, R., & Zott, C. (2001). Value creation in E-business. Strategic Management Journal, 22(6–7), 493–520.CrossRef

Ang, S. H. (2008). Competitive intensity and collaboration: Impact on firm growth across technological environments. Strategic Management Journal, 29(10), 1057–1075.CrossRef

Baum, J. A. C., Calabrese, T., & Silverman, B. S. (2000). Don’t go it alone: Alliance network composition and startups’ performance in Canadian biotechnology. Strategic Management Journal, 21(3), 267–294.CrossRef

Baum, J. A. C., & Silverman, B. S. (2004). Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups. Journal of Business Venturing, 19(3), 411–436.CrossRef

Behnke, N., & Hültenschmidt, N. (2007). New path to profits in biotech: Taking the acquisition exit. Journal of Commercial Biotechnology, 13(2), 78–85.CrossRef

Bresser, R., Heuskel, D., & Nixon, R. (2000). The deconstruction of integrated value chains: Practical and conceptual challenges. In R. Bresser, M. Hitt, R. Nixon, & D. Heuskel (Eds.), Winning strategies in a deconstructing world (pp. 1–50). Chichester: John Wiley & Sons.

Carayannopoulos, S., & Auster, E. R. (2010). External knowledge sourcing in biotechnology through acquisition versus alliance: A KBV approach. Research Policy, 39(2), 254–267.CrossRef

Cooke, P. (2007). The financing of biopharmaceutical firms. In P. Cooke (Ed.), Growth cultures: The global bioeconomy and its bioregions (pp. 214–243). New York: Routledge.

De Carolis, D. M. (2003). Competencies and imitability in the pharmaceutical industry: An analysis of their relationship with firm performance. Journal of Management, 29(1), 27–50.

Deeds, D. L., & Hill, C. W. L. (1996). Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms. Journal of Business Venturing, 11(1), 41–55.CrossRef

DiMaggio, P. J., & Powell, W. W. (1983). The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. American Sociological Review, 48(2), 147–160.CrossRef

DiMasi, J. A., & Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics, 28(4–5), 469–479.CrossRef

DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151–185.CrossRef

Durand, R., Bruyaka, O., & Mangematin, V. (2008). Do science and money go together? The case of the French biotech industry. Strategic Management Journal, 29(12), 1281–1299.CrossRef

Fildes, R. A. (1990). Strategic challenges in commercializing biotechnology. California Management Review, 32(3), 63–72.

Fisken, J., & Rutherford, J. (2002). Business models and investment trends in the biotechnology industry in Europe. Journal of Commercial Biotechnology, 8(3), 191–199.

Fried, V. H., & Hisrich, R. D. (1995). The venture capitalist: A relationship investor. California Management Review, 37(2), 101–113.

Ghaziani, A., & Ventresca, M. J. (2005). Keywords and cultural change: Frame analysis of business model public talk, 1975–2000. Sociological Forum, 20(4), 523–559.CrossRef

Glick, J. L. (2008). Biotechnology business models work: Evidence from the pharmaceutical marketplace. Journal of Commercial Biotechnology, 14(2), 106–117.CrossRef

Gupta, A. K., Smith, K. G., & Shalley, C. E. (2006). The interplay between exploration and exploitation. Academy of Management Journal, 49(4), 693–706.CrossRef

Haeussler, C. (2007). Proactive versus reactive M&A activities in the biotechnology industry. Journal of High Technology Management Research, 17(2), 109–123.CrossRef

Hagedoorn, J. (1993). Understanding the rationale of strategic technology partnering: Interorganizational modes of cooperation and sectoral differences. Strategic Management Journal, 14(5), 371–385.CrossRef

Hagedoorn, J., & Duysters, G. (2002). Learning in dynamic inter-firm networks: The efficacy of multiple contacts. Organization Studies, 23(4), 525–548.CrossRef

Harianto, F., & Pennings, J. M. (1994). Technological convergence and scope of organizational innovation. Research Policy, 23(3), 293–304.CrossRef

Inkpen, A. C. (2000). Learning through joint ventures: A framework of knowledge acquisition. Journal of Management Studies, 37(7), 1019–1043.CrossRef

Kogut, B. (1988). Joint ventures: Theoretical and empirical perspectives. Strategic Management Journal, 9(4), 319–332.CrossRef

Kolchinsky, P. (2004). The entrepreneur’s guide to a biotech startup. Boston: Evelexa.

Konde, V. (2009). Biotechnology business models: An Indian perspective. Journal of Commercial Biotechnology, 15(3), 215–226.CrossRef

Kotabe, M., & Swan, K. S. (1995). The role of strategic alliances in high-technology new product development. Strategic Management Journal, 16(8), 621–636.CrossRef

Koza, M. P., & Lewin, A. Y. (1998). The co-evolution of strategic alliances. Organization Science, 9(3), 255–264.CrossRef

Lechner, C., & Dowling, M. (1999). The evolution of industrial districts and regional networks: The case of the biotechnology region Munich/Martinsried. Journal of Management and Governance, 3(4), 309–338.CrossRef

Lerner, J., Shane, H., & Tsai, A. (2003). Do equity financing cycles matter? Evidence from biotechnology alliances. Journal of Financial Economics, 67(3), 411–446.CrossRef

Levinthal, D. A., & March, J. G. (1993). The myopia of learning. Strategic Management Journal, 14(Winter Special Issue), 95–112.CrossRef

Magretta, J. (2002). Why business models matter. Harvard Business Review, 80(5), 86–92.

Mangematin, V., Lemarié, S., Boissin, J., Catherine, D., Corolleur, F., Coronini, R., et al. (2003). Development of SMEs and heterogeneity of trajectories: The case of biotechnology in France. Research Policy, 32(4), 621–638.CrossRef

March, J. G. (1991). Exploration and exploitation in organizational learning. Organization Science, 2(1), 71–87.CrossRef

Maybeck, V., & Bains, W. (2006). Small company mergers—good for whom? Nature Biotechnology, 24(11), 1343–1348.CrossRef

McNamara, P., & Baden-Fuller, C. (2007). Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms. Research Policy, 36(4), 548–565.CrossRef

Meyer, J. W., & Rowan, B. (1977). Institutionalized organizations: Formal structure as myth and ceremony. American Journal of Sociology, 83(2), 340–363.CrossRef

Nosella, A., Petroni, G., & Verbano, C. (2005). Characteristics of the Italian biotechnology industry and new business models: The initial results of an empirical study. Technovation, 25(8), 841–855.CrossRef

Onetti, A., Zucchella, A., Jones, M. V., & McDougall-Covin, P. P. (2010). Internationalization, innovation and entrepreneurship: Business models for new technology-based firms. Journal of Management and Governance, Special Issue on “Entrepreneurship and Strategic Management in Life Sciences. Business Models for High-Tech Companies”.

Pavlou, A. K., & Belsey, M. J. (2005). The therapeutic antibodies market to 2008. European Journal of Pharmaceutics and Biopharmaceutics, 59(3), 389–396.CrossRef

Powell, W. W., Koput, K. W., & Smith-Doerr, L. (1996). Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology. Administrative Science Quarterly, 41(1), 116–145.CrossRef

Roijakkers, N., & Hagedoorn, J. (2006). Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks. Research Policy, 35(3), 431–446.CrossRef

Rothaermel, F. T. (2001). Incumbent’s advantage through exploiting complementary assets via interfirm cooperation. Strategic Management Journal, 22(6–7), 687–699.CrossRef

Rothaermel, F. T., & Deeds, D. L. (2004). Exploration and exploitation alliances in biotechnology: A system of new product development. Strategic Management Journal, 25(3), 201–221.CrossRef

Rothman, H., & Kraft, A. (2006). Downstream and into deep biology: Evolving business models in ‘top tier’ genomics companies. Journal of Commercial Biotechnology, 12(2), 86–97.CrossRef

Schweizer, L. (2005). Concept and evolution of business models. Journal of General Management, 31(2), 37–56.

Shan, W., Walker, G., & Kogut, B. (1994). Interfirm cooperation and startup innovation in the biotechnology industry. Strategic Management Journal, 15(5), 387–394.CrossRef

Stuart, T. E., Ozdemir, S. Z., & Ding, W. W. (2007). Vertical alliance networks: The case of university-biotechnology-pharmaceutical alliance chains. Research Policy, 36(4), 477–498.CrossRef

Tyebjee, T., & Hardin, J. (2004). Biotech-pharma alliances: Strategies, structures and financing. Journal of Commercial Biotechnology, 10(4), 329–339.CrossRef

Uotila, J., Maula, M., Keil, T., & Zahra, S. A. (2009). Exploration, exploitation, and financial performance: Analysis of S&P 500 corporations. Strategic Management Journal, 30(2), 221–231.CrossRef

Williamson, O. E. (1975). Markets and hierarchies: Analysis and antitrust implications. New York: The Free Press.

Xu, B. (2006). Market differential evaluations of strategic alliances in the pharmaceutical/biotech industry. Journal of High Technology Management Research, 17(1), 43–52.CrossRef

Zott, C., & Amit, R. (2008). The fit between product market strategy and business model: Implications for firm performance. Strategic Management Journal, 29(1), 1–26.CrossRef

Titel: Biotechnology collaborations: does business model matter?
verfasst von: Raphael Greiner
Siah Hwee Ang
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Management and Governance / Ausgabe 3/2012
Print ISSN: 1385-3457
Elektronische ISSN: 1572-963X
DOI: https://doi.org/10.1007/s10997-010-9156-z

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 3/2012

Internationalization, innovation and entrepreneurship: business models for new technology-based firms

Transnational social capital and scientist entrepreneurship

Wholly proprietary versus wholly open knowledge strategies: some empirical evidences from Italian biotech firms

Innovation and export performance: a study of Italian high-tech SMEs

Guest editor’s introduction to the special issue: entrepreneurship and strategic management in new technology based companies

Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms

Premium Partner